PAULETTE ANDERSON: Open Payments
NPI 1205020161 · CHESTERTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$310 in 14 payments from 7 companies in 2025. Trend: 2023 $359 · 2024 $484 · 2025 $310
Food & beverage: $310
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $77 |
| Neurocrine BioSciences, Inc. | 3 | $51 |
| Alkermes, Inc. | 2 | $49 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| ABBVIE INC. | 2 | $37 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: CAPLYTA, INGREZZA, ARISTADA, COBENFY, VRAYLAR, INVEGA SUSTENNA, HETLIOZ.
Industry payments across MD — which companies pay providers there.
